Esketamine Exposure Impairs Cardiac Development and Function in Zebrafish Larvae

Shuo Huang, Jingyi Wang, Tingting Lin, Chengyong He, Zhiyuan ChenToxics 2024 · DOI

TL;DR

This study reveals that esketamine exposure during early development in zebrafish larvae significantly impairs cardiac development and function. The findings suggest that esketamine disrupts crucial gene expression related to heart development and calcium signaling, leading to structural abnormalities and reduced cardiac output, highlighting the need for a thorough safety assessment of this widely used anesthetic.

What Problem Does This Paper Address?

Esketamine is a widely used anesthetic and antidepressant, but its long-term safety, particularly concerning developmental toxicity, remains incompletely understood. While its neurotoxic effects have been studied, its impact on cardiac development, especially in vulnerable populations like developing fetuses and children, is less clear. This paper addresses this knowledge gap by investigating the specific effects of esketamine exposure on the developing heart in a model organism, zebrafish, aiming to elucidate potential mechanisms of cardiac toxicity.

Methods

The researchers utilized zebrafish embryos as their model system. They exposed embryos to varying concentrations of esketamine (1, 10, and 100 mg/L) from 48 to 72 hours post-fertilization (hpf). Key techniques included:

  • Developmental Toxicity Assessment: Monitoring hatching rates and mortality.
  • Cardiac Function Analysis: Measuring heart rate, end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), and cardiac output (CO) using automated tracking and image analysis.
  • Morphological Imaging: Using transgenic Tg(cmlc2:EGFP) zebrafish, which express GFP in cardiac muscle cells, to visualize and quantify cardiac structures like atrial wall thickness and ventricular cross-sectional area using confocal microscopy.
  • Gene Expression Analysis: Employing quantitative real-time PCR (RT-qPCR) to assess the expression levels of genes critical for cardiac development (e.g., nkx2.5, gata4, tbx5, myh6) and calcium signaling pathways (e.g., ryr2a, atp2a2a, cacna1aa).
  • Neurotransmitter Analysis: Measuring acetylcholine (Ach) levels and the activities of acetylcholinesterase (AchE) and choline acetyltransferase (ChAT) to investigate potential neurohumoral regulatory mechanisms.

Datasets

Not discussed in the paper. The study relies on experimental data generated from zebrafish embryos and larvae.

Key Insights and Ideas

  • Esketamine's Dual Nature: While esketamine is known for its anesthetic properties, this study highlights its potential for significant developmental toxicity, particularly affecting the cardiovascular system.
  • Beyond Neurotoxicity: The research expands the understanding of esketamine's risks beyond its well-documented neurotoxic effects, focusing on the critical developmental window of the heart.
  • Mechanism of Impairment: The study proposes a multi-faceted mechanism involving disruption of cardiac development genes, dysregulation of calcium signaling, and altered acetylcholine levels, suggesting a complex interplay of factors leading to cardiac dysfunction.
  • Hormesis in Action? The observed dose-dependent effects on gene expression, with some genes showing increased expression at lower doses and decreased at higher doses, hints at hormetic responses, where low doses might stimulate certain pathways while high doses are inhibitory.

Key Results

  • Developmental Effects: Esketamine exposure did not significantly increase mortality but did lead to a marginal increase in hatching rates at 60 hpf.
  • Cardiac Function Impairment: At 72 hpf, esketamine exposure, particularly at 100 mg/L, significantly decreased heart rate, stroke volume, and cardiac output.
  • Morphological Abnormalities: Transgenic zebrafish exposed to esketamine showed thickening of atrial walls and dilation of ventricles, indicating structural defects.
  • Gene Expression Dysregulation:
    • Genes involved in cardiac development (nkx2.5, gata4, myh6) showed altered expression patterns, with some upregulated at lower concentrations. tbx5 expression was significantly downregulated.
  • Genes in the calcium signaling pathway (ryr2a, ryr2b, atp2a2a, atp2a2b, slc8a3, slc8a4a, cacna1aa) exhibited dose-dependent decreases in expression, suggesting impaired calcium homeostasis.
  • Neurotransmitter Changes: Esketamine exposure led to increased acetylcholine (Ach) levels and altered activities of AchE and ChAT, suggesting a disruption in neural regulation of the heart.

Limitations and Future Work

The authors acknowledge that their study has limitations, primarily stemming from the reliance on experimental observations and analytical results. They emphasize the need for further research to fully understand how esketamine affects zebrafish heart function. Future work could focus on:

  • Investigating the precise molecular interactions and signaling cascades involved in esketamine-induced cardiac toxicity.
  • Exploring the long-term consequences of early esketamine exposure on cardiac health beyond the larval stage.
  • Translating these findings to mammalian models to assess the relevance to human development.
  • Further elucidating the role of acetylcholine in mediating esketamine's cardiac effects.

Summary updated

Abstract

Esketamine is a widely used intravenous general anesthetic. However, its safety, particularly its effects on the heart, is not fully understood. In this study, we investigated the effects of esketamine exposure on zebrafish embryonic heart development. Zebrafish embryos were exposed to esketamine at concentrations of 1, 10, and 100 mg/L from 48 h post-fertilization (hpf) to 72 hpf. We found that after exposure, zebrafish embryos had an increased hatching rate, decreased heart rate, stroke volume, and cardiac output. When we exposed transgenic zebrafish of the Tg(<i>cmlc2:EGFP</i>) strain to esketamine, we observed ventricular dilation and thickening of atrial walls in developing embryos. Additionally, we further discovered the abnormal expression of genes associated with cardiac development, including <i>nkx2.5</i>, <i>gata4</i>, <i>tbx5</i>, and <i>myh6</i>, calcium signaling pathways, namely <i>ryr2a</i>, <i>ryr2b</i>, <i>atp2a2a</i>, <i>atp2a2b</i>, <i>slc8a3</i>, <i>slc8a4a</i>, and <i>cacna1aa</i>, as well as an increase in acetylcholine concentration. In conclusion, our findings suggest that esketamine may impair zebrafish larvae's cardiac development and function by affecting acetylcholine concentration, resulting in weakened cardiac neural regulation and subsequent effects on cardiac function. The insights garnered from this research advocate for a comprehensive safety assessment of esketamine in clinical applications.
BibTeX
@inproceedings{huang2024esketamine,
  author = {Shuo Huang and Jingyi Wang and Tingting Lin and Chengyong He and Zhiyuan Chen},
  title = {{Esketamine Exposure Impairs Cardiac Development and Function in Zebrafish Larvae}},
  booktitle = {Toxics},
  year = {2024},
  doi = {10.3390/toxics12060427},
}
Figure